Pharma stocks traded mostly in positive territory on June 24, 2026, during the early session, with 18 out of 23 counters either rising or staying near flat. The sector outperformed the broader market as the S&P BSE Healthcare index gained 0.31% to 48,680.12 around 9:48–9:49 AM, while the Nifty 50 was almost unchanged and the Sensex posted modest gains.
The broader market remained subdued, with the Nifty 50 down 0.02% at 23,819.35 and the S&P BSE Sensex up 0.24% at 76,382.09. Against that backdrop, pharma shares found support, with strong buying seen in several frontline and midcap names.
Among the top gainers, Orchid Pharma led the pack, rising 3.72% on BSE to ₹1,024.95 and 2.21% on NSE to ₹1,011.50. Dr. Reddy’s Laboratories followed with gains of 2.38% on BSE to ₹1,332.30 and 2.39% on NSE to ₹1,332.40. Natco Pharma climbed 1.62% on BSE and 1.36% on NSE, while Lupin advanced 1.52% on BSE and 1.40% on NSE.
Ajanta Pharma also posted a healthy move, rising 1.20% on BSE to ₹3,227.15. Other notable gainers included Sudeep Pharma, Wockhardt, Indoco Remedies, Aurobindo Pharma, Mankind Pharma, Cipla, Zydus Lifesciences, Divis Laboratories, Sun Pharma, IPCA Labs and J.B. Chemicals. Most of these names posted modest gains, indicating broad-based but selective buying across the sector.
On the losing side, Panacea Biotech was the weakest performer, slipping 1.18% on BSE and 1.74% on NSE. Aarti Drugs, Glenmark Pharma and Alembic Pharma also ended lower, though losses were limited. Biocon was nearly flat, showing only a marginal decline on both exchanges.
The early trade pointed to a steady day for pharma stocks, with gains outnumbering declines by a wide margin. The sector’s relative strength suggested investors were still showing interest in healthcare counters even as the wider market moved in a narrow range.
*Disclaimer: Investments in equities and securities are subject to market risks. The information provided in this article is for informational and educational purposes only and should not be construed as investment advice, stock recommendations, or financial guidance. Investors should conduct their own research and consult qualified financial advisors before making any investment decisions. Past performance is not indicative of future results. Market conditions can change rapidly, and there is no guarantee of future returns. Always assess your risk tolerance, financial goals, and investment horizon before investing in any security or financial product.
